Building at the intersection of molecular engineering and surgery.

Amyno Bio is an early-stage biotechnology company working to bring molecular specificity into the surgical field of view. We combine engineering-led development with input from clinicians to investigate new approaches to intraoperative imaging.

Make more anatomy distinguishable.

Our goal is to give surgical teams clear visual information about structures that are hard to identify. Molecular imaging is a promising way to do it, and we are building from focused laboratory research.

Our founders.

Portrait of Noah Kahn

Noah Kahn

Co-Founder & CEO

Noah conducts live-cell fluorescence microscopy research at the Tay Lab and designed a medical device now advancing toward manufacturing at Eclipse Regenesis. He studies Molecular Engineering (Bioengineering track) at the University of Chicago.

Portrait of Amy Schechter

Amy Schechter

Co-Founder

Amy has worked across medtech and biotech startups, including Theranova and Nestera Health, and was Head of Operations at Tilden Therapeutics. She studies Molecular Engineering (Bioengineering track) at the University of Chicago.

Science first. Clinical context throughout.

The work began with clinical observation. Noah shadowed robotic and open surgeries through Fogarty Innovation, and we have since discussed the concept with more than a dozen surgeons, including surgical oncologists, at hospitals across the country. Our focus is on generating evidence before making claims about clinical utility.

Founded in 2026, Amyno was awarded early non-dilutive funding by LTF, and our laboratory access is provided by an agreement with the University of Chicago.